| Similar Articles |
|---|
 |
Bio-IT World
July 14, 2004
Davies & Russell |
The Sweet Hereafter Novartis' stunning new research home in a former candy factory is but one ingredient in a bold new recipe for success that embraces leadership, culture, science, and technology.   |
Pharmaceutical Executive
April 10, 2014
Christini & Kaitin |
Regional Trends in Bioinnovation Investment Can the Cambridge model be duplicated? |
Bio-IT World
October 14, 2004
Robinson & Violino |
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape. |
Bio-IT World
July 14, 2004 |
Not Just a Day at the Beach Joseph Panetta recalls leaving the comfort of a pharma job in Philadelphia for a position in biotech in San Diego, whose fledgling biotech community survived stormy nascent years to mushroom into a biotech hotbed. |
Chemistry World
December 2006
Derek Lowe |
Opinion: In the Pipeline A look at the story behind the growing investment by western companies in medicinal chemistry research in China. |
CFO
December 1, 2006
Kate O'Sullivan |
Biotech Dreaming Cities and states in the U.S. are vying to become biotechnology hot spots. Ultimately, some regions may not have enough of the key ingredients for biotech success. |
Chemistry World
June 4, 2015
Phillip Broadwith |
Takeda to consolidate vaccines business in Boston Japanese pharma firm Takeda plans to close three US sites and move the headquarters of its vaccines business unit to the pharmaceutical hub in the Boston and Cambridge area of Massachusetts. |
Job Journal
August 8, 2004
Rich Heintz |
Biotech's Winning Formula for Steady Job Growth Deep pockets are creating expanding opportunities and biotechnology is helping to put America back to work. |
Chemistry World
November 1, 2012
Andrew Turley |
Novartis biotech plant for Singapore The new plant, which will make drugs through cell culture, will be located with the Novartis production plant at Tuas. |
The Motley Fool
November 6, 2006
Brian Gorman |
Novartis' China Gambit Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore. Investors, take note. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
Chemistry World
June 19, 2013
Laura Howes |
AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city. |
The Motley Fool
July 15, 2010
Ryan McBride |
Glaxo's Tempero Pharma Advances on Hot Niche of Immunology Staking claim in emerging fields. |
Bio-IT World
June 15, 2003
Barbara Depompa |
Northwest Region Colorado: Biotech Summit in Denver... Utah: A Mecca for Genealogical Research... Washington State: Therapeutics and Diagnostics Niche... |
Bio-IT World
June 15, 2003
Barbara Depompa |
Southwest Region Texas: Bioscience with a Space Spin... New Mexico: Building a Bioinformatics Niche... Arizona: Focus on Cancer and Neurological Therapy... Southern California: Deep Biotech Roots Grow Many Branches... Northern California: 'Can You Afford To Be Elsewhere?'... |
National Real Estate Investor
June 1, 2003
H. Lee Murphy |
Who's Behind Biotech? There is a niche in the office market where vacancies are a fraction of the national rate, rents are way above average, and prospects for growth actually exist. It is the specialized (and regionally concentrated) business of supplying space to the biotech and life sciences industry. |
Chemistry World
April 25, 2014
Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. |
Bio-IT World
April 2006
Laura Huckabee-Jennings |
Southern Emergence Why Huntsville, Alabama, will be the next biotech hotbed. |
BusinessWeek
June 11, 2009
Kerry Capell |
Novartis: Radically Remaking Its Drug Business CEO Dan Vasella's growth mantra for Novartis is follow the science, not the financials. |
Chemistry World
November 6, 2013
Laura Howes |
Novartis to shut Horsham site Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D. |
Bio-IT World
April 2007 |
News Briefs Molecular Medicine's "Best of Show"... Dissolving Assets... Combined Forces... |
BusinessWeek
November 6, 2006
Nichola Saminather |
Biotech's Beef There is a disconnect between what universities are teaching and what biotech wants. |
Bio-IT World
June 15, 2003
Bob Violino |
Mid-Atlantic/Southeast Region Maryland: Making a Federal Case for Biotechnology... Puerto Rico: Isle of Incentives... Virginia: Planting Needed Seed Capital... North Carolina: Triangulating Biotech Resources... Florida: Shining Resources on Small Biotech Sector |
Chemistry World
November 30, 2012
Andy Extance |
Chemists cull compounds using 'intuition' Medicinal chemists might be using far fewer parameters to choose candidate fragments for a screening collection than they think they do. Their choices can be mimicked based on just one or two properties, a team led by researchers at Swiss-headquarted pharmaceutical firm Novartis has found. |
The Motley Fool
July 16, 2009
Brian Orelli |
A Strong Dollar Can Hurt Novartis makes it through a hard quarter. |
BusinessWeek
September 27, 2004
Kerry Capell |
How Dublin Keeps Big Pharma Happy By providing cheap yet educated workers and giving tax breaks to big investors, the Irish have turned their country into a major drug manufacturing center. |
The Motley Fool
August 13, 2007
Andrew R. Vaino |
Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow. |
Bio-IT World
November 2005
Mark D. Uehling |
The Unstoppable Swiss At a time when other pharmaceutical giants struggle to justify pediatric uses of their medicines, or to defend themselves against thousands of lawsuits, Novartis has one of the safest and strongest pipelines in the industry. |
Pharmaceutical Executive
October 1, 2005 |
Successful Alliances: Novartis and Idenix Share the Secrets of Success Novartis Pharma AG CEO Thomas Ebeling and Idenix founder, CEO, and chairman Jean-Pierre Sommadossi discuss the mutual benefits and challenges of maintaining a successful partnership. |
The Motley Fool
June 14, 2005
Rich Duprey |
Chiron's Credit Conundrum Standard & Poor's downgrades the biotech's credit rating on seemingly old news. Why now? |
The Motley Fool
November 12, 2009
Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
The Motley Fool
September 20, 2005
Brian Gorman |
Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note. |
Pharmaceutical Executive
March 12, 2012
William Looney |
Novartis: LEADing in Emerging Markets With growth as its guiding light, Novartis has big plans for the emerging markets. CEO Joe Jimenez tells us what it will take the company to best the competition. |
IndustryWeek
November 1, 2002
Tonya Vinas |
Questioning Biotech's Benefits While most communities are investing to attract or grow biotechnology companies, a recent report concludes that only a handful of cities will benefit in the long run. |
Job Journal
July 16, 2006
Julia Hollister |
Biotech Boom The biotech field offers promising jobs in a profession that's expanding faster than you can spell biotherapeutics. |
Bio-IT World
March 2007
Kevin Davies |
Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges. |
The Motley Fool
December 15, 2004
Brian Gorman |
Korea's Biotech Bet Korea's new facility could stimulate biotech research in Asia and lower costs for biotech companies. |
Commercial Investment Real Estate
May/Jun 2005
Bell & Drummond |
Biotech Boom Biotech tenants have specific needs for lab/office space, but they do not need a physical link to a city's business center. In addition to biotech, the nanotech and biopharmaceutical industries are also growing quickly. |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week. |
Chemistry World
January 24, 2014
Phillip Broadwith |
Novartis and DSM trim jobs Pharmaceutical firm Novartis and nutritional products specialist DSM are both set to cut jobs in Switzerland. |
The Motley Fool
July 15, 2005
Stephen D. Simpson |
Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit. |
The Motley Fool
September 1, 2005
Stephen D. Simpson |
Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note. |
The Motley Fool
January 22, 2007
Brian Lawler |
Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough. |
The Motley Fool
December 13, 2011
Frank Vinluan |
N.C. Novartis Site Is First Cell-Based Flu Vaccine Facility in the Country A Novartis' vaccine facility in North Carolina today became the first facility authorized by the FDA for emergency use during a pandemic. |
Pharmaceutical Executive
October 1, 2011
Daniel Vasella |
Heart of Success: Patient-Centric R&D Drug discovery must remain a core competency of industry. The future success of individual companies will be tightly linked to success in R&D. |
The Motley Fool
March 16, 2006
Rich Duprey |
Chiron's Shareholder Revolt Hedge funds oppose the biotech's buyout by pharmaceutical giant Novartis. Investors, take note. |
The Motley Fool
July 21, 2004
Brian Gorman |
Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity. |
The Motley Fool
March 29, 2006
Stephen D. Simpson |
Novartis Bulks Up Its Pipeline The Swiss drug giant once again pays up to add trial candidates to its portfolio. Investors, take note. |
The Motley Fool
July 17, 2007
Brian Lawler |
Still Strong at Novartis For investors who are willing to filter the negative news and are patient enough to wait for recently launched branded compounds to help its top-line growth, Novartis is worth a look |
